Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -362.2%. (2006–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $579314 | $126892 | — | — | — | — | — | — | — | — | — |
| Enterprise Value | $-9950457 | $-10402879 | — | — | — | — | — | — | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.00 | 0.01 | — | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -362.2% | -362.2% | — | -619.8% | -141.3% | -118.8% | — | -3005.9% | -499.7% | -328.0% | -174.7% |
| ROA | -193.0% | -193.0% | -29.0% | -58.2% | -53.3% | -47.1% | -832.3% | -328.6% | -215.8% | -205.7% | -161.0% |
| ROIC | -1245.4% | -1245.4% | — | — | — | — | — | -840.7% | -524.4% | -915.6% | -172.0% |
| ROCE | -341.2% | -341.2% | -280.4% | -69.5% | -30.8% | -26.7% | — | -3230.6% | -459.4% | -327.8% | -171.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.00 | — | — | 1.19 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.61 | — | — | -3.97 | -2.07 | — | — | 0.42 | -1.35 | -0.17 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -735.71 | -735.71 | — | — | -27413.61 | -88.81 | -133.64 | -198.70 | -244.40 | — | — |
Net cash position: cash ($11M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.01 | 5.01 | 0.49 | 14.96 | 45.00 | 103.81 | 0.07 | 0.15 | 1.40 | 1.84 | 17.15 |
| Quick Ratio | 5.01 | 5.01 | 0.49 | 14.96 | 45.00 | 103.81 | 0.07 | 0.15 | 1.40 | 1.84 | 17.15 |
| Cash Ratio | 4.49 | 4.49 | 0.12 | 11.80 | 43.61 | 102.85 | 0.01 | 0.14 | 1.31 | 1.82 | 16.89 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $423114 | $109699 | $104131 | $103293 | $30130 | $4759 | $3864 | $2852 | $2264 | $1923 |
Clinical trial funding dependency
As reported in financial statements, BCTXZ's ROIC has remained deeply negative, reaching -66.9% in 2026Q3, which highlights the company's inability to generate productive returns on invested capital while it remains in the high-cost, pre-revenue phase of its clinical development lifecycle.
The persistent decay in ROIC, which plummeted to -157.0% in 2026Q2, suggests that the capital deployed into the SV-BR-1 platform is currently failing to create economic value. Investors should monitor whether future clinical milestones can reverse this trend, as the current trajectory indicates that capital is being consumed rather than compounded.
Based on recent SEC filings, BCTXZ's current ratio has exhibited extreme volatility, swinging from 10.19 in 2026Q2 to 7.07 in 2026Q3, which underscores the company's precarious reliance on periodic equity infusions to maintain its short-term liquidity position.
While the current ratio appears superficially high, it is largely a function of the timing of capital raises rather than operational cash generation. This suggests that the company's liquidity position is highly sensitive to market conditions, warranting further investigation into the sustainability of its cash runway.
According to historical data, the company's DPO has reached as high as 11,375 days in 2025Q4, which suggests that BCTXZ is managing its cash outflows by significantly delaying payments to suppliers, a common but unsustainable tactic for firms facing severe capital constraints.
The lack of meaningful asset turnover or cash conversion cycle metrics reflects the company's pre-revenue status and its focus on R&D rather than commercial operations. This reliance on extended payables may indicate that the company is attempting to stretch its limited cash reserves as far as possible.
As noted in industry research, the use of P/E or EV/EBITDA ratios for BCTXZ is fundamentally flawed, as these metrics obscure the company's lack of commercial revenue and the binary nature of its clinical trial outcomes.
Investors should instead focus on cash runway and probability-weighted clinical success, as traditional valuation multiples are rendered meaningless by the absence of earnings. Relying on standard valuation metrics may lead to a significant misinterpretation of the company's true risk-reward profile.
Includes 30+ ratios · 20 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BCTXZ stock.
BriaCell Therapeutics Corp. Warrant's current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
BriaCell Therapeutics Corp. Warrant's return on equity (ROE) is -362.2%. The historical average is -144.7%.
Based on historical data, BriaCell Therapeutics Corp. Warrant is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.